Gilotrif
/
Gilotrif (afatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) mutations. It is administered as an oral tablet and is available by prescription only. Patients are advised that Gilotrif may cause diarrhea and should be monitored for severe gastrointestinal symptoms, as well as potential liver function abnormalities.
FAQs about Gilotrif
What should I do if I miss a dose?
If you miss a dose of Gilotrif, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is found in the Patient Counseling Information section of the label.
Can I take Gilotrif while pregnant or breastfeeding?
The use of Gilotrif during pregnancy is not recommended due to potential harm to the fetus. Women who are pregnant or planning to become pregnant should discuss the risks with their healthcare provider. It is not known if afatinib is excreted in human milk, so breastfeeding while taking Gilotrif is not recommended. This information is detailed in the Warnings and Precautions section of the label.
Can I stop taking Gilotrif suddenly?
Patients are advised not to stop taking Gilotrif without consulting their healthcare provider, as abrupt discontinuation may affect treatment outcomes. Follow your prescriber\
25
commonly-prescribed
medication.